<DOC>
	<DOCNO>NCT00040417</DOCNO>
	<brief_summary>The major goal study determine risk benefit stem cell transplant combination newer , less toxic conditioning chemotherapy treatment patient severe sickle cell disease ( SCD ) sickle hemoglobin variant ( hemoglobin SC hemoglobin SB0/+ ) , homozygous b0/+ thalassemia severe B0/+ thalassemia variant . Participation project one year , follow evaluation do every 6 month thereafter 10 year participants 18 year old .</brief_summary>
	<brief_title>Bone Marrow Transplant From Donor Using Less Toxic Conditioning Patient With High Risk Hemoglobinopathies</brief_title>
	<detailed_description>To stem cell transplant , must first kill cell bone marrow make sickle hemoglobin abnormal blood cell severe beta thalassemia . We use single dose body irradiation two drug call Fludarabine Campath-IH . The treatment schedule follow : Day - 6 : Total body irradiation Day - 5 : Fludarabine Campath 1H Day - 4 : Fludarabine Campath 1H Day - 3 : Fludarabine Campath 1H Day - 2 : Fludarabine Campath 1H Day - 1 : REST Day 0 : Stem Cell Transplant ( infusion ) After drug treatment , participant give healthy stem cell relate donor partially match HLA ( immune ) type , likely parent sibling . This known stem cell transplant . The healthy stem cell put blood vein way transfusion give . The cell travel right place body , grow make new blood cell sickle .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Inclusion : Patients haploidentical related HLA donor hemoglobin SS , hemoglobin SC , hemoglobin Sb0/+ thalassemia least one follow condition : 1. previous central nervous system vasoocclusive episode without residual neurologic finding ; 2. frequent painful vasoocclusive episode significantly interfere normal life activity necessitate chronic transfusion therapy ; 3. recurrent SCD chest syndrome event , necessitate chronic transfusion therapy ; 4. severe anemia , prevents acceptable quality life necessitates chronic transfusion therapy . Patients haploidentical related HLA donor homozygous b0/+ thalassemia severe variant b0/+ thalassemia require chronic transfusion therapy . Women childbearing potential must negative pregnancy test . Between age birth 65 year . Exclusion : HLA identical 5/6 HLA match sibling donor Biopsy proven chronic active hepatitis portal fibrosis . SCD chronic lung disease &gt; stage 3 Severe renal dysfunction define creatinine clearance &lt; 40 ml/min/1.73 M2 . Severe cardiac dysfunction define shorten fraction &lt; 25 % . HIV infection . Unspecified chronic toxicity serious enough detrimentally affect patient 's capacity tolerate Stem Cell Transplant . Patient guardian ( ) unable understand nature risk inherent stem cell transplant process . Pregnant lactating female unwilling use acceptable contraception .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>